• Je něco špatně v tomto záznamu ?

Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy

AJ. Church, ML. Calicchio, V. Nardi, A. Skalova, A. Pinto, DA. Dillon, CR. Gomez-Fernandez, N. Manoj, JD. Haimes, JA. Stahl, FS. Dela Cruz, S. Tannenbaum-Dvir, JL. Glade-Bender, AL. Kung, SG. DuBois, HP. Kozakewich, KA. Janeway, AR. Perez-Atayde,...

. 2018 ; 31 (3) : 463-473. [pub] 20171103

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028704

Infantile fibrosarcoma and congenital mesoblastic nephroma are tumors of infancy traditionally associated with the ETV6-NTRK3 gene fusion. However, a number of case reports have identified variant fusions in these tumors. In order to assess the frequency of variant NTRK3 fusions, and in particular whether the recently identified EML4-NTRK3 fusion is recurrent, 63 archival cases of infantile fibrosarcoma, congenital mesoblastic nephroma, mammary analog secretory carcinoma and secretory breast carcinoma (tumor types that are known to carry recurrent ETV6-NTRK3 fusions) were tested with NTRK3 break-apart FISH, EML4-NTRK3 dual fusion FISH, and targeted RNA sequencing. The EML4-NTRK3 fusion was identified in two cases of infantile fibrosarcoma (one of which was previously described), and in one case of congenital mesoblastic nephroma, demonstrating that the EML4-NTRK3 fusion is a recurrent genetic event in these related tumors. The growing spectrum of gene fusions associated with infantile fibrosarcoma and congenital mesoblastic nephroma along with the recent availability of targeted therapies directed toward inhibition of NTRK signaling argue for alternate testing strategies beyond ETV6 break-apart FISH. The use of either NTRK3 FISH or next-generation sequencing will expand the number of cases in which an oncogenic fusion is identified and facilitate optimal diagnosis and treatment for patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028704
003      
CZ-PrNML
005      
20190823102334.0
007      
ta
008      
190813s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/modpathol.2017.127 $2 doi
035    __
$a (PubMed)29099503
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Church, Alanna J $u Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
245    10
$a Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy / $c AJ. Church, ML. Calicchio, V. Nardi, A. Skalova, A. Pinto, DA. Dillon, CR. Gomez-Fernandez, N. Manoj, JD. Haimes, JA. Stahl, FS. Dela Cruz, S. Tannenbaum-Dvir, JL. Glade-Bender, AL. Kung, SG. DuBois, HP. Kozakewich, KA. Janeway, AR. Perez-Atayde, MH. Harris,
520    9_
$a Infantile fibrosarcoma and congenital mesoblastic nephroma are tumors of infancy traditionally associated with the ETV6-NTRK3 gene fusion. However, a number of case reports have identified variant fusions in these tumors. In order to assess the frequency of variant NTRK3 fusions, and in particular whether the recently identified EML4-NTRK3 fusion is recurrent, 63 archival cases of infantile fibrosarcoma, congenital mesoblastic nephroma, mammary analog secretory carcinoma and secretory breast carcinoma (tumor types that are known to carry recurrent ETV6-NTRK3 fusions) were tested with NTRK3 break-apart FISH, EML4-NTRK3 dual fusion FISH, and targeted RNA sequencing. The EML4-NTRK3 fusion was identified in two cases of infantile fibrosarcoma (one of which was previously described), and in one case of congenital mesoblastic nephroma, demonstrating that the EML4-NTRK3 fusion is a recurrent genetic event in these related tumors. The growing spectrum of gene fusions associated with infantile fibrosarcoma and congenital mesoblastic nephroma along with the recent availability of targeted therapies directed toward inhibition of NTRK signaling argue for alternate testing strategies beyond ETV6 break-apart FISH. The use of either NTRK3 FISH or next-generation sequencing will expand the number of cases in which an oncogenic fusion is identified and facilitate optimal diagnosis and treatment for patients.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádory prsu $x genetika $7 D001943
650    _2
$a karcinom $x genetika $7 D002277
650    _2
$a proteiny buněčného cyklu $x genetika $7 D018797
650    _2
$a předškolní dítě $7 D002675
650    _2
$a receptor DDR2 $x genetika $7 D000070820
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibrosarkom $x diagnóza $x genetika $7 D005354
650    _2
$a genetické testování $7 D005820
650    _2
$a lidé $7 D006801
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a nádory ledvin $x vrozené $x diagnóza $x genetika $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a proteiny asociované s mikrotubuly $x genetika $7 D008869
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $x genetika $7 D009364
650    _2
$a mezoblastický nefrom $x vrozené $x diagnóza $x genetika $7 D018201
650    _2
$a fúzní onkogenní proteiny $x genetika $7 D015514
650    _2
$a protoonkogenní proteiny c-ets $x genetika $7 D050783
650    _2
$a represorové proteiny $x genetika $7 D012097
650    _2
$a sekvenční analýza RNA $7 D017423
650    _2
$a serinové endopeptidasy $x genetika $7 D012697
655    _2
$a časopisecké články $7 D016428
700    1_
$a Calicchio, Monica L $u Department of Pathology, Boston Children's Hospital, Boston, MA, USA.
700    1_
$a Nardi, Valentina $u Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
700    1_
$a Skalova, Alena $u Department of Pathology, Charles University, Faculty of Medicine in Plzen, Plzen, Czech Republic.
700    1_
$a Pinto, Andre $u Department of Pathology, University of Miami, Miami, FL, USA.
700    1_
$a Dillon, Deborah A $u Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
700    1_
$a Gomez-Fernandez, Carmen R $u Department of Pathology, University of Miami, Miami, FL, USA.
700    1_
$a Manoj, Namitha $u ArcherDX, Boulder, CO, USA.
700    1_
$a Haimes, Josh D $u ArcherDX, Boulder, CO, USA.
700    1_
$a Stahl, Joshua A $u ArcherDX, Boulder, CO, USA.
700    1_
$a Dela Cruz, Filemon S $u Department of Pediatrics, Memorial Sloan Kettering Cancer Institute, New York, NY, USA.
700    1_
$a Tannenbaum-Dvir, Sarah $u Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Columbia University Medical Center, New York, NY, USA.
700    1_
$a Glade-Bender, Julia L $u Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Columbia University Medical Center, New York, NY, USA.
700    1_
$a Kung, Andrew L $u ArcherDX, Boulder, CO, USA.
700    1_
$a DuBois, Steven G $u Department of Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA.
700    1_
$a Kozakewich, Harry P $u Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
700    1_
$a Janeway, Katherine A $u Department of Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA.
700    1_
$a Perez-Atayde, Antonio R $u Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
700    1_
$a Harris, Marian H $u Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
773    0_
$w MED00003380 $t Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc $x 1530-0285 $g Roč. 31, č. 3 (2018), s. 463-473
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29099503 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190823102548 $b ABA008
999    __
$a ok $b bmc $g 1433853 $s 1067164
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 31 $c 3 $d 463-473 $e 20171103 $i 1530-0285 $m Modern pathology $n Mod Pathol $x MED00003380
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace